OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
|Videos|May 16, 2022
Dr. Rafael Sanchez-Salas on the ideal patient for focal therapy for prostate cancer
Author(s)Urology Times staff
“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.
Advertisement
In this interview, Rafael Sanchez-Salas, MD, also discusses potential complications of focal therapy. Sanchez-Salas is an associate professor of urology in the department of surgery at McGill University in Montreal, Quebec.
Advertisement
Related to this article
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Advertisement
Advertisement